Skip to main content
SpringerLink
Log in

Nonbranded ciclosporin use appears to be associated with increased healthcare costs due to higher pharmacy and inpatient utilisation

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Helderman JH, Kang N, GILMORE AS, Ryskina KL, Legorreta AP.An economic evaluation of de novo renal transplant recipients using branded vs. non-branded cyclosporine modified. World Transplant Congress: The First Joint International Transplant Meeting: 115 abstr. 143, 22 Jul 2006

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nonbranded ciclosporin use appears to be associated with increased healthcare costs due to higher pharmacy and inpatient utilisation. Pharmacoecon. Outcomes News 511, 7 (2006). https://doi.org/10.2165/00151234-200605110-00018

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200605110-00018

Keywords

Search

Navigation